Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kala Pharmaceuticals Inc (KALA)

Kala Pharmaceuticals Inc (KALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,618
  • Shares Outstanding, K 72,594
  • Annual Sales, $ 11,240 K
  • Annual Income, $ -142,610 K
  • 60-Month Beta 1.01
  • Price/Sales 1.94
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KALA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.13
  • Most Recent Earnings -0.45 on 05/16/22
  • Next Earnings Date 08/04/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 471.73% ( +111.34%)
  • Historical Volatility 111.49%
  • IV Percentile 88%
  • IV Rank 33.61%
  • IV High 1,311.19% on 06/16/22
  • IV Low 46.73% on 08/18/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 4,525
  • Open Int (30-Day) 5,449

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.38
  • Number of Estimates 3
  • High Estimate -0.30
  • Low Estimate -0.43
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2810 +5.98%
on 07/01/22
0.4290 -30.58%
on 06/09/22
-0.0622 (-17.28%)
since 06/01/22
3-Month
0.2810 +5.98%
on 07/01/22
1.3900 -78.58%
on 04/05/22
-1.0122 (-77.27%)
since 04/01/22
52-Week
0.2810 +5.98%
on 07/01/22
5.4700 -94.56%
on 07/02/21
-5.1322 (-94.52%)
since 07/01/21

Most Recent Stories

More News
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., June 17, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory...

KALA : 0.2978 (-0.73%)
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the...

KALA : 0.2978 (-0.73%)
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3...

KALA : 0.2978 (-0.73%)
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

KALA : 0.2978 (-0.73%)
VBLT : 1.6300 (+1.24%)
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q...

KALA : 0.2978 (-0.73%)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DARE : 1.1900 (-3.25%)
KALA : 0.2978 (-0.73%)
Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TRVN : 0.3900 (-5.80%)
KALA : 0.2978 (-0.73%)
Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ATNX : 0.4330 (+5.76%)
KALA : 0.2978 (-0.73%)
Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the...

KALA : 0.2978 (-0.73%)
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed...

KALA : 0.2978 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes,...

See More

Key Turning Points

3rd Resistance Point 0.3394
2nd Resistance Point 0.3243
1st Resistance Point 0.3111
Last Price 0.2978
1st Support Level 0.2828
2nd Support Level 0.2677
3rd Support Level 0.2545

See More

52-Week High 5.4700
Fibonacci 61.8% 3.4878
Fibonacci 50% 2.8755
Fibonacci 38.2% 2.2632
Last Price 0.2978
52-Week Low 0.2810

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar